Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The effect of certolizumab drug concentration and anti-drug antibodies on TNF neutralisation.
Berkhout LC, Vogelzang EH, Hart MM, Loeff FC, Dijk L, Derksen NIL, Wieringa R, van Leeuwen WA, Krieckaert CLM, de Vries A, Nurmohamed MT, Wolbink GJ, Rispens T. Berkhout LC, et al. Among authors: de vries a. Clin Exp Rheumatol. 2020 Mar-Apr;38(2):306-313. doi: 10.55563/clinexprheumatol/nlr4r8. Epub 2019 Aug 30. Clin Exp Rheumatol. 2020. PMID: 31498069 Free article.
Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis.
Tsakok T, Wilson N, Dand N, Loeff FC, Bloem K, Baudry D, Duckworth M, Pan S, Pushpa-Rajah A, Standing JF, de Vries A, Alsharqi A, Becher G, Murphy R, Wahie S, Wright A, Griffiths CEM, Reynolds NJ, Barker J, Warren RB, Burden AD, Rispens T, Stocken D, Smith C; British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) Study Group and the Psoriasis Stratification to Optimise Relevant Therapy (PSORT) Consortium. Tsakok T, et al. Among authors: de vries a. JAMA Dermatol. 2019 Nov 1;155(11):1235-1243. doi: 10.1001/jamadermatol.2019.1783. JAMA Dermatol. 2019. PMID: 31532460 Free PMC article.
Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study.
Pan S, Tsakok T, Dand N, Lonsdale DO, Loeff FC, Bloem K, de Vries A, Baudry D, Duckworth M, Mahil S, Pushpa-Rajah A, Russell A, Alsharqi A, Becher G, Murphy R, Wahie S, Wright A, Griffiths CEM, Reynolds NJ, Barker J, Warren RB, David Burden A, Rispens T, Standing JF, Smith CH; BADBIR Study Group, the BSTOP Study Group, the PSORT Consortium. Pan S, et al. Among authors: de vries a. Clin Transl Sci. 2020 Mar;13(2):400-409. doi: 10.1111/cts.12725. Epub 2020 Jan 29. Clin Transl Sci. 2020. PMID: 31995663 Free PMC article.
Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study.
Loeff FC, Tsakok T, Dijk L, Hart MH, Duckworth M, Baudry D, Russell A, Dand N, van Leeuwen A, Griffiths CEM, Reynolds NJ, Barker J, Burden AD, Warren RB, de Vries A, Bloem K, Wolbink GJ, Smith CH, Rispens T; BADBIR; BSTOP Study Groups; PSORT consortium. Loeff FC, et al. Among authors: de vries a. J Invest Dermatol. 2020 Nov;140(11):2129-2137. doi: 10.1016/j.jid.2020.03.957. Epub 2020 Apr 10. J Invest Dermatol. 2020. PMID: 32283057 Free article.
Comprehensive evaluation of microneedle-based intradermal adalimumab delivery vs. subcutaneous administration: results of a randomized controlled clinical trial.
Jacobse J, Ten Voorde W, Tandon A, Romeijn SG, Grievink HW, van der Maaden K, van Esdonk MJ, Moes DJAR, Loeff F, Bloem K, de Vries A, Rispens T, Wolbink G, de Kam M, Ziagkos D, Moerland M, Jiskoot W, Bouwstra J, Burggraaf J, Schrier L, Rissmann R, Ten Cate R. Jacobse J, et al. Among authors: de kam m, de vries a. Br J Clin Pharmacol. 2021 Aug;87(8):3162-3176. doi: 10.1111/bcp.14729. Epub 2021 Feb 2. Br J Clin Pharmacol. 2021. PMID: 33403697 Free PMC article. Clinical Trial.
EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases.
Krieckaert CL, van Tubergen A, Gehin JE, Hernández-Breijo B, Le Mélédo G, Balsa A, Böhm P, Cucnik S, Elkayam O, Goll GL, Hooijberg F, Jani M, Kiely PD, McCarthy N, Mulleman D, Navarro-Compán V, Payne K, Perry ME, Plasencia-Rodriguez C, Stones SR, Syversen SW, de Vries A, Ward KM, Wolbink G, Isaacs JD. Krieckaert CL, et al. Among authors: de vries a. Ann Rheum Dis. 2023 Jan;82(1):65-73. doi: 10.1136/annrheumdis-2022-222155. Epub 2022 May 12. Ann Rheum Dis. 2023. PMID: 35551063
Development of antidrug antibodies against adalimumab maps to variation within the HLA-DR peptide-binding groove.
Tsakok T, Saklatvala J, Rispens T, Loeff FC, de Vries A, Allen MH, Barbosa IA, Baudry D, Dasandi T, Duckworth M, Meynell F, Russell A, Chapman A, McBride S, McKenna K, Perera G, Ramsay H, Ramesh R, Sands K, Shipman A; Biomarkers of Systemic Treatment Outcomes in Psoriasis (BSTOP) Study Group; Burden AD, Griffiths CE, Reynolds NJ, Warren RB, Mahil S, Barker J, Dand N, Smith C, Simpson MA. Tsakok T, et al. Among authors: de vries a. JCI Insight. 2023 Feb 22;8(4):e156643. doi: 10.1172/jci.insight.156643. JCI Insight. 2023. PMID: 36810251 Free PMC article.
Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial.
Wientjes MHM, Atiqi S, Wolbink GJ, Nurmohamed MT, Boers M, Rispens T, de Vries A, van Vollenhoven RF, van den Bemt BJF, den Broeder AA. Wientjes MHM, et al. Among authors: de vries a. Trials. 2021 Jun 19;22(1):406. doi: 10.1186/s13063-021-05358-7. Trials. 2021. PMID: 34147123 Free PMC article.
2,104 results